News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Atrial Cardiopathy And Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Study Status:

Study Closed

Contact Information:

(956) 362-2391

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of the ARCADIA study is to test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial Cardiopathy.

Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

Information: 

Principal Investigator
Wady Aude, M.D.
Co-PI
Esmeralda Cordoso-Mendoza
Sponsor
Columbia University / National Institute of Neurological Disorders and Stroke (NINDS)
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram